drill citrón mentol tvrdé pastilky
pierre fabre medicament, francúzsko - chlórhexidín - 69 - otorhinolaryngologica
drill ruŽový med tvrdé pastilky
pierre fabre medicament , francúzsko - chlórhexidín - 69 - otorhinolaryngologica
gemcitabine accord 200 mg
accord healthcare polska sp. z o.o., poľsko - gemcitabín - 44 - cytostatica
gemcitabine accord 1 g
accord healthcare polska sp. z o.o., poľsko - gemcitabín - 44 - cytostatica
hidrasec pre dojčatá 10 mg
bioprojet europe limited, Írsko - racekadotril - 49 - digestiva, adsorbentia, acida
hidrasec pre deti 30 mg
bioprojet europe limited, Írsko - racekadotril - 49 - digestiva, adsorbentia, acida
hidrasec 100 mg
bioprojet europe limited, Írsko - racekadotril - 49 - digestiva, adsorbentia, acida
gemcitabine accord 2 g
accord healthcare polska sp. z o.o., poľsko - gemcitabín - 44 - cytostatica
bloctil 100 mg tvrdé kapsuly
rivopharm limited, Írsko - racekadotril - 49 - digestiva, adsorbentia, acida
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.